Is Greater Trochanteric Pain Syndrome Linked to Menopause?
Yes, greater trochanteric pain syndrome (GTPS) is strongly associated with menopause and is particularly prevalent in postmenopausal women. The condition predominantly affects middle-aged and postmenopausal women, with the hormonal changes following menopause appearing to play a significant pathophysiological role 1, 2, 3.
The Evidence for the Menopause-GTPS Link
Epidemiological Association
GTPS affects approximately 17.6% of adults aged 50-79 years, with a striking female predominance 4. The condition is specifically described as "most prevalent in postmenopausal women" and "particularly affects middle-aged women" 1, 3. The incidence rate reaches 1.8 patients per 1,000 annually, with females disproportionately affected 5.
Hormonal Mechanism
The pathophysiological connection centers on estrogen's role in tendon health. A positive association exists between high estrogen levels and tendon health, while postmenopausal women have reduced estrogen that may negatively affect tendon integrity 1, 6. This hormonal deficiency appears to predispose women to gluteus medius and minimus tendinopathy—the primary pathology underlying GTPS 2.
Clinical Trial Evidence
The most compelling evidence comes from a 2022 factorial randomized controlled trial (Level 1 evidence) that specifically investigated menopausal hormone therapy (MHT) for GTPS 1. This study of 132 postmenopausal women demonstrated:
- For women with BMI <25, MHT combined with exercise and education produced significantly better outcomes than placebo at all time points (baseline: P=0.04; 12 weeks: P<0.001; 52 weeks: P=0.002)
- The effect was specific to leaner women, suggesting body composition modulates the hormone-tendon relationship
- MHT used transdermal estradiol 50mcg with norethisterone acetate 140mcg
Important Caveats
BMI Matters
The therapeutic benefit of MHT was only significant in women with BMI <25 1. This interaction effect between hormonal status and body composition is critical—the hormonal contribution to GTPS pathology may be overshadowed by mechanical factors in women with higher BMI.
Broader Musculoskeletal Context
While the association appears strong, a definitive causal link between estrogen deficiency and musculoskeletal pain remains incompletely established 7. Musculoskeletal pain and arthralgia generally increase with age and menopause onset, but isolating the specific hormonal contribution from other age-related factors remains challenging 7.
Diagnostic Considerations
GTPS is often misdiagnosed as trochanteric bursitis when the primary pathology is actually gluteal tendinopathy 2, 3. Accurate diagnosis requires clinical assessment combined with diagnostic imaging (ultrasound or MRI) to identify tendon pathology rather than assuming isolated bursitis.
Clinical Implications
The menopause-GTPS link has direct treatment implications. The 2022 RCT showed that all intervention groups (including sham exercise with education) improved significantly over 12 weeks (P<0.001), but MHT provided additional benefit in appropriate candidates 1. This suggests that while education about avoiding gluteal tendon compression and load management forms the foundation of treatment, hormonal supplementation may enhance outcomes in postmenopausal women with lower BMI.
The evidence does not support using MHT solely for GTPS prevention or treatment outside the context of other menopausal symptoms, as general menopause guidelines recommend against MHT for primary disease prevention 8. However, for symptomatic postmenopausal women already considering MHT for vasomotor symptoms who also have GTPS, the potential tendon benefits represent an additional consideration.